Anticoagulant effects of hirulog, ∗∗Hirulog™ brand direct thrombin inhibitor. a novel thrombin inhibitor, in patients with coronary artery disease

This publication has 27 references indexed in Scilit:

• Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency
  Journal of the American College of Cardiology, 1992
• Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
  Heart, 1992
• Structure‐function relationships of hirulog peptide interactions with thrombin
  FEBS Letters, 1991
• Heparin
  New England Journal of Medicine, 1991
• Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
  Cell, 1991
• Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
  The American Journal of Cardiology, 1990
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
  Journal of Clinical Investigation, 1990
• The Structure of a Complex of Recombinant Hirudin and Human α-Thrombin
  Science, 1990
• Aspirin, Heparin, or Both to Treat Acute Unstable Angina
  New England Journal of Medicine, 1988
• Effect of heparin bonding on catheter-induced fibrin formation and platelet activation.
  Circulation, 1984